LENVIMA

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Spain, UK.

Active ingredients

The drug LENVIMA contains one active pharmaceutical ingredient (API):

1	Lenvatinib UNII 3J78384F61 - LENVATINIB MESYLATE
	Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), in addition to other proangiogenic and oncogenic pathway-related RTKs including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4, the platelet derived growth factor (PDGF) receptor PDGFRα, KIT, and RET.
	Read more about Lenvatinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LENVIMA Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EX08		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10952K, 10965D, 11638M
BR	Câmara de Regulação do Mercado de Medicamentos	533219110002217, 533219110002317
CA	Health Products and Food Branch	02450291, 02450305, 02450313, 02450321, 02468220, 02468239, 02484056, 02484129
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	5275-MEE-0720, 5280-MEE-0720
EE	Ravimiamet	1687181, 1687192, 1818817, 1818828, 1818851, 1818862, 1849697, 1849709
ES	Centro de información online de medicamentos de la AEMPS	1151002001, 1151002002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	387479, 478672
FR	Base de données publique des médicaments	62093424, 64456664
GB	Medicines & Healthcare Products Regulatory Agency	298651, 298654
HK	Department of Health Drug Office	64507, 64508
IE	Health Products Regulatory Authority	88386, 88391
IL	מִשְׂרַד הַבְּרִיאוּת	7824, 7825
IT	Agenzia del Farmaco	044200018, 044200020, 044200032, 044200044, 044200057, 044200069
JP	医薬品医療機器総合機構	4291039M1020, 4291039M2027
LT	Valstybinė vaistų kontrolės tarnyba	1076775, 1076776, 1090398, 1090399, 1090400, 1090401
NL	Z-Index G-Standaard, PRK	133256, 133299
NZ	Medicines and Medical Devices Safety Authority	20962, 20963
PL	Rejestru Produktów Leczniczych	100347485, 100347491
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66655001, W66655002, W66655003, W66656001, W66656002, W66656003
SG	Health Sciences Authority	14982P, 14983P
US	FDA, National Drug Code	62856-704, 62856-708, 62856-710, 62856-712, 62856-720